Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Diabetes clinical trials

Directory of U.S. ClinicalTrials.gov public records for Diabetes. Browse Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 28, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
8332
Shown on this page
12
Current sort
Recently updated
Condition scope
Diabetes
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Diabetes studies are organized in the registry

Generic “diabetes” listings mix type 1, type 2, and gestational diabetes, so the subtype is the first thing to pin down — this directory also has a dedicated type 2 diabetes page. Device studies (continuous glucose monitors, insulin delivery systems) are a large slice of the portfolio and are easiest to find by querying the device term itself.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Diabetes. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 289–300 of 8,332 matching trials for Diabetes.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Not yet recruiting Not applicable Interventional

The RESPLASH Study

NCT06880562
Conditions
Resistant Hypertension
Interventions
Splanchnic Nerve Denervation, Renal Denervation Only
Device
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Huntington Park, California • Northridge, California • Santa Ana, California + 18 more
Conditions
Obesity, Type 2 Diabetes
Interventions
Cagrisema, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
99
States / cities
Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more
Conditions
Diabetes
Interventions
MOSES
Behavioral
Lead sponsor
Baltimore Research & Education Foundation, Inc.
Other
Eligibility
60 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Results available

Glycemic Effect of Diazoxide in NAFLD

NCT05729282
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Interventions
Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O)
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
CagriSema
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
40
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendora, California + 37 more
Conditions
Obesity & Overweight, Prediabetes
Interventions
Precision Nutrition Intervention, Standard Nutrition Counseling
Behavioral
Lead sponsor
Prairie View A&M University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Prairie View, Texas
Conditions
Diabetes Mellitus, Overweight, Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Lomita, California + 12 more
Conditions
Type 2 Diabetes
Interventions
PATAS Trifluoroacetate, Placebo
Drug
Lead sponsor
AdipoPharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Chandler, Arizona • Miami, Florida • Port Orange, Florida
Completed Not applicable Interventional Results available

Changing Health Through Food Support for Diabetes

NCT04959487
Conditions
Type 2 Diabetes, Food Insecurity
Interventions
Food support, Nutritional Counseling and education
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Obesity and Overweight, Diabetes Mellitus, Weight Loss, Behavior Change
Interventions
Family Skills Training Session Quantity: 5, Family Skills Training Session Mode: In-person, Family Skills Training Content: Communication, Family Skills Training Content: Cohesion, Family Skills Training Session Quantity: 10, Family Skills Training Session Mode: Online, Family Skills Training Content: No Communication, Family Skills Training Content: No Cohesion
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Diabetes, Diabetes Type 2
Interventions
Integrated Digital Health (IDH) platform, Provider engagement
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut

About this Diabetes clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Diabetes.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Diabetes.